Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Blood Urea and Creatinine Stability Determined for Chemistry Analyzer

By Labmedica International staff writers
Posted on 17 Dec 2013
Advia 1800 Chemistry Analyzer System (Photo courtesy of Siemens).
Advia 1800 Chemistry Analyzer System (Photo courtesy of Siemens).
Serum creatinine values of patients tend to change as a result of the use of different blanks used for creatinine determinations on some clinical chemistry analyzers.

A general quality assurance program in clinical chemistry laboratories is an essential part of monitoring the stabilities of determinations on what are commonly known as stat analytes, including sodium, potassium, chloride, bicarbonate, calcium, glucose, blood urea nitrogen (BUN), and creatinine.

Medical laboratory scientists at the New York Harbor Veteran Affairs Medical Center (Brooklyn, NY, USA) investigated the reproducibility of creatinine values, by determining the serial creatinine values in the sera of 13 patients whose initial values were either in the reference range or elevated (range 0.58 to 7.8 mg/dL). They determined BUN and creatinine values, using the glutamate dehydrogenase linked enzyme assay system and the Jaffe method, respectively.

Determination of all values was performed on the Siemens Advia 1800 chemistry analyzer (Siemens Healthcare; Tarrytown, NY, USA) using the method for creatinine, which uses the formation of a complex of creatinine with picric acid, and for BUN values urease-catalyzed release of ammonia was measured by the glutamate dehydrogenase system. The creatinine values were determined concurrently with serum blood urea nitrogen (BUN) determinations, range 6.0 to 84.4 mg/dL, as these two analytes are used together in evaluation of renal function.

The scientists found that all values for creatinine on samples stored at 4 °C were reproducible as were the corresponding BUN values, which is revealed by low values for the coefficients of variation (CV). One sample with relatively high CV of 10.6% for creatinine was found to have an initial value of 1.1 mg/dL, in the reference range; but, on repeat determinations, the obtained levels were as high as 1.5 mg/dL, above the reference range. BUN values for this sample remained in the reference range, suggesting that no renal disease was present.

The authors concluded that the precision of the serum BUN assays on the Advia 1800 analyzer is quite high over the prolonged time period of 15 days. The same conclusion applies to serum creatinine assay results on this analyzer with the caveat that borderline values can show less precision-making evaluation of renal function more difficult. The study was published on November 11, 2013, in the Journal of Clinical Laboratory Analysis.

Related Links:

New York Harbor Veteran Affairs Medical Center
Siemens Healthcare

EUROIMMUN AG
PURITAN MEDICAL
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.